Published in J Pharmacol Exp Ther on March 01, 2000
Neurocircuitry of addiction. Neuropsychopharmacology (2010) 14.22
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J Neurosci (2009) 2.30
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci (2011) 1.83
Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci (2008) 1.62
Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol (2002) 1.53
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology (Berl) (2006) 1.45
Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) (2005) 1.35
Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav Pharmacol (2008) 1.23
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.19
Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology (Berl) (2004) 1.16
Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats. Psychopharmacology (Berl) (2003) 1.11
Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) (2005) 1.09
The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog Neurobiol (2010) 1.09
Tobacco addiction and the dysregulation of brain stress systems. Neurosci Biobehav Rev (2012) 1.09
Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology (2009) 1.08
Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology (Berl) (2008) 1.07
Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats. Neuropsychopharmacology (2006) 1.04
Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies. Pharmacol Biochem Behav (2008) 1.04
Deficits in a sustained attention task following nicotine withdrawal in rats. Psychopharmacology (Berl) (2004) 1.04
Activation of GABAergic neurons in the interpeduncular nucleus triggers physical nicotine withdrawal symptoms. Curr Biol (2013) 1.04
Withdrawal from chronic nicotine in adolescent and adult rats. Pharmacol Biochem Behav (2006) 1.03
Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine. Neuropsychopharmacology (2009) 1.03
Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur J Pharmacol (2006) 1.02
Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology (2007) 1.01
A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats. Psychopharmacology (Berl) (2011) 1.00
Nicotine withdrawal-induced deficits in trace fear conditioning in C57BL/6 mice--a role for high-affinity beta2 subunit-containing nicotinic acetylcholine receptors. Eur J Neurosci (2009) 1.00
Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats. Pharmacol Biochem Behav (2010) 1.00
Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats. Behav Pharmacol (2010) 0.99
Mechanistic insights into nicotine withdrawal. Biochem Pharmacol (2011) 0.98
The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse. Neuropharmacology (2013) 0.97
Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacol Biochem Behav (2009) 0.97
Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) (2005) 0.95
Role of α7- and β4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice. Behav Genet (2011) 0.92
The role of various nicotinic receptor subunits and factors influencing nicotine conditioned place aversion. Neuropharmacology (2009) 0.92
Historical and current perspective on tobacco use and nicotine addiction. Trends Neurosci (2011) 0.91
Association between nicotine withdrawal and reward responsiveness in humans and rats. JAMA Psychiatry (2014) 0.91
Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum. Psychopharmacology (Berl) (2008) 0.90
Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS One (2011) 0.90
Exposure to chronic intermittent nicotine vapor induces nicotine dependence. Pharmacol Biochem Behav (2010) 0.89
Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology (Berl) (2012) 0.89
Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin. Neuropharmacology (2009) 0.89
Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. Psychopharmacology (Berl) (2011) 0.88
Precipitated withdrawal from nicotine reduces reinforcing effects of a visual stimulus for rats. Nicotine Tob Res (2012) 0.87
Medication-related pharmacological manipulations of nicotine self-administration in the rat maintained on fixed- and progressive-ratio schedules of reinforcement. Psychopharmacology (Berl) (2008) 0.87
Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking. Front Psychiatry (2013) 0.87
Potentiated startle as a measure of the negative affective consequences of repeated exposure to nicotine in rats. Psychopharmacology (Berl) (2009) 0.87
The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur Neuropsychopharmacol (2010) 0.86
Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats. Psychopharmacology (Berl) (2010) 0.86
Influence of δ-opioid receptors in the behavioral effects of nicotine. Neuropsychopharmacology (2012) 0.85
Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology (Berl) (2007) 0.84
Dose, duration, and pattern of nicotine administration as determinants of behavioral dependence in rats. Psychopharmacology (Berl) (2005) 0.84
Desensitization of δ-opioid receptors in nucleus accumbens during nicotine withdrawal. Psychopharmacology (Berl) (2010) 0.83
Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Mecamylamine elicits withdrawal-like signs in rats following a single dose of nicotine. Psychopharmacology (Berl) (2012) 0.82
Intracranial self-stimulation reward thresholds during morphine withdrawal in rats bred for high (HiS) and low (LoS) saccharin intake. Brain Res (2015) 0.82
Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology (2013) 0.80
Nicotine withdrawal and kappa-opioid receptors. Psychopharmacology (Berl) (2009) 0.79
The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys. Behav Pharmacol (2014) 0.79
Non-cholinergic modulation of antisaccade performance: a modafinil-nicotine comparison. Psychopharmacology (Berl) (2007) 0.78
Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehav Rev (2015) 0.78
Nicotinic receptor contributions to smoking: insights from human studies and animal models. Curr Addict Rep (2015) 0.78
Cognitive control deficits during mecamylamine-precipitated withdrawal in mice: Possible links to frontostriatal BDNF imbalance. Neurobiol Learn Mem (2016) 0.77
The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice. Psychopharmacology (Berl) (2014) 0.77
Null mutation of the β2 nicotinic acetylcholine receptor subunit attenuates nicotine withdrawal-induced anhedonia in mice. Eur J Pharmacol (2014) 0.77
Mouse models for studying genetic influences on factors determining smoking cessation success in humans. Ann N Y Acad Sci (2012) 0.77
Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Psychopharmacology (Berl) (2014) 0.76
[The endogenous opioid system and drug addiction]. Ann Pharm Fr (2010) 0.76
A Two-Day Continuous Nicotine Infusion Is Sufficient to Demonstrate Nicotine Withdrawal in Rats as Measured Using Intracranial Self-Stimulation. PLoS One (2015) 0.75
Effects of continuous nicotine treatment and subsequent termination on cocaine versus food choice in male rhesus monkeys. Exp Clin Psychopharmacol (2015) 0.75
Blockade of cholinergic transmission elicits somatic signs in nicotine-naïve adolescent rats. Front Pharmacol (2015) 0.75
Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology (Berl) (2016) 0.75
Smoking Cessation and the Risk of Hyperactive Delirium in Hospitalized Patients: A Retrospective Study. Can J Psychiatry (2016) 0.75
Endogenous opioid system: a promising target for future smoking cessation medications. Psychopharmacology (Berl) (2017) 0.75
Transition from moderate to excessive drug intake: change in hedonic set point. Science (1998) 5.66
Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science (1993) 3.67
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res (2000) 3.33
Dramatic decreases in brain reward function during nicotine withdrawal. Nature (1998) 3.21
Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology (2000) 3.15
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Suppression of psychoactive effects of cocaine by active immunization. Nature (1995) 3.05
Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet (2000) 3.04
Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology (1998) 2.96
Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend (1998) 2.94
Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther (1993) 2.79
Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci (1995) 2.70
Effects of moderate alcohol consumption on the central nervous system. Alcohol Clin Exp Res (1998) 2.60
Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol Clin Exp Res (1996) 2.51
Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science (1997) 2.50
Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology (1991) 2.41
Animal models of drug craving. Psychopharmacology (Berl) (1993) 2.32
Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res (1993) 2.27
Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A (2000) 2.16
Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berl) (1984) 2.13
Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell (1994) 2.05
Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology (2000) 2.04
CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl) (1991) 2.04
Long-lasting increase in the set point for cocaine self-administration after escalation in rats. Psychopharmacology (Berl) (1999) 2.01
Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci U S A (1995) 2.00
Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav (1992) 1.96
Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci (1996) 1.95
GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Eur J Pharmacol (1995) 1.93
Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science (1996) 1.91
Corticotropin releasing factor produces behavioural activation in rats. Nature (1982) 1.82
A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A (2001) 1.78
Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci (2001) 1.78
Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement. Psychopharmacology (Berl) (1996) 1.77
Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology (Berl) (1982) 1.76
Dopaminergic terminals in the rat cortex. Science (1973) 1.73
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav (2001) 1.67
mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther (2000) 1.67
Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. Brain Res Cogn Brain Res (1999) 1.66
Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci (1994) 1.65
Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci (1994) 1.61
Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res (1992) 1.60
Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res (1995) 1.59
Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav (1999) 1.58
Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci (1982) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Neural substrates of opiate withdrawal. Trends Neurosci (1992) 1.52
Cocaine- but not food-seeking behavior is reinstated by stress after extinction. Psychopharmacology (Berl) (1997) 1.50
Modulation of social memory in male rats by neurohypophyseal peptides. Psychopharmacology (Berl) (1987) 1.49
Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol Biochem Behav (1980) 1.48
Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J Pharmacol Exp Ther (1994) 1.47
Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl) (1999) 1.46
Operant self-administration of sweetened versus unsweetened ethanol: effects on blood alcohol levels. Alcohol Clin Exp Res (1999) 1.45
Genetic differences in response to novelty and spatial memory using a two-trial recognition task in mice. Neurobiol Learn Mem (2000) 1.44
Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: effects of conditioned cues and continuous access to cocaine. Psychopharmacology (Berl) (1998) 1.44
Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology (1993) 1.43
Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science (1993) 1.43
Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav (1982) 1.41
Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl) (1986) 1.38
Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology (Berl) (1992) 1.38
Time-dependent quantifiable withdrawal from ethanol in the rat: effect of method of dependence induction. Alcohol (1996) 1.35
Drugs of abuse and the brain. Proc Assoc Am Physicians (1999) 1.35
Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res (1992) 1.35
Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J Pharmacol Exp Ther (1994) 1.35
Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev (1989) 1.33
Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther (1992) 1.29
Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res (2001) 1.29
Opponent process model and psychostimulant addiction. Pharmacol Biochem Behav (1997) 1.29
Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci (2003) 1.28
Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience (1990) 1.28
Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Alcohol Clin Exp Res (1997) 1.26
Some evidence for the existence of dopaminergic neurons in the rat cortex. Brain Res (1973) 1.26
Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat. Eur J Pharmacol (1994) 1.26
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology (2001) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology (2002) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry (1986) 1.17
Dependence-induced alcohol drinking by alcohol-preferring (P) rats and outbred Wistar rats. Alcohol Clin Exp Res (2008) 1.16
The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann N Y Acad Sci (1994) 1.16
Corticotropin-releasing factor and behavior. Fed Proc (1985) 1.15
Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol Clin Exp Res (1999) 1.15
Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis. Eur J Neurosci (2007) 1.15
The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res (1999) 1.14
CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res (2000) 1.14
The effects of 6-hydroxydopamine lesions of the nucleus accumbens and the mesolimbic dopamine system on oral self-administration of ethanol in the rat. Brain Res (1993) 1.14
Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology (1989) 1.13